Stockholm, 25 June 2018 @ 09:00:00. “Tio, nio, åtta … tre, två, ett”, in this very moment, and with the sound of the bell, Nuevolution AB (publ) opened the financial markets in Stockholm and started trading of its shares (ticker: NUE) on Nasdaq Stockholm main market.
Nuevolution AB (publ) is a leading small molecule drug discovery biotech company founded in 2001, and headquartered in Copenhagen, Denmark. Nuevolution partners its discovery platform and programs with pharmaceutical and biotechnology companies to seek future benefit of patients in need of novel medical treatment option. Nuevolution’s internal programs are focused on therapeutically important targets within inflammation, oncology and immuno-oncology.